BioCentury | Apr 15, 2013
Clinical News

Ovarex anti-ideotype vaccine data

...patients on Ovarex was 40.7 percent compared with 11.4 percent for patients on conventional chemotherapy. Altarex...
BioCentury | Dec 20, 2004
Company News

AltaRex, ViRexx Medical deal

...exclusive financial advisor for VIR and Orion Securities was the exclusive financial advisor to ALT. AltaRex Medical Corp....
BioCentury | Sep 20, 2004
Company News

Ziopharm Inc. management update

...Conn. Business: Cancer Hired: Richard Bagley as president and COO, formerly president and CEO of AltaRex...
BioCentury | Jul 12, 2004
Company News

AltaRex Corp., Dompe International S.A. sales and marketing update

...The murine monoclonal antibody against CA125 is in Phase III testing to treat ovarian cancer. AltaRex...
BioCentury | Aug 18, 2003
Company News

AltaRex Corp., United Therapeutics deal

...UTHR already has worldwide rights to resulting products, excluding the EU and certain other countries. AltaRex...
BioCentury | Jun 9, 2003
Clinical News

OvaRex MAb: Phase II data; Phase III

...and chemotherapy. Data were presented at the American Society of Clinical Oncology meeting in Chicago. AltaRex...
BioCentury | Jun 2, 2003
Finance

Restructuring watch

...reduce its quarterly cash burn to $6-$7 million. $49.1 3/31 $7.5 1Q ended 3/31 5/15/03 AltaRex...
BioCentury | May 19, 2003
Company News

AltaRex Corp. board of directors update

AltaRex Corp. (TSE:AXO; ALXFF), Waltham, Mass. Business: Cancer Appointed: Antoine Noujaim, AXO founder Resigned: Richard Bagley WIR Staff...
BioCentury | May 19, 2003
Company News

AltaRex Corp. management update

AltaRex Corp. (TSE:AXO; ALXFF), Waltham, Mass. Business: Cancer Resigned: Richard Bagley as president and CEO; he will be replaced by AXO founder Antoine Noujam WIR Staff cancer...
BioCentury | May 12, 2003
Clinical News

OvaRex MAb: Phase II comparability data; Phase III

...I and II studies as well as other ongoing Phase II trials in the U.S. AltaRex...
Items per page:
1 - 10 of 111
BioCentury | Apr 15, 2013
Clinical News

Ovarex anti-ideotype vaccine data

...patients on Ovarex was 40.7 percent compared with 11.4 percent for patients on conventional chemotherapy. Altarex...
BioCentury | Dec 20, 2004
Company News

AltaRex, ViRexx Medical deal

...exclusive financial advisor for VIR and Orion Securities was the exclusive financial advisor to ALT. AltaRex Medical Corp....
BioCentury | Sep 20, 2004
Company News

Ziopharm Inc. management update

...Conn. Business: Cancer Hired: Richard Bagley as president and COO, formerly president and CEO of AltaRex...
BioCentury | Jul 12, 2004
Company News

AltaRex Corp., Dompe International S.A. sales and marketing update

...The murine monoclonal antibody against CA125 is in Phase III testing to treat ovarian cancer. AltaRex...
BioCentury | Aug 18, 2003
Company News

AltaRex Corp., United Therapeutics deal

...UTHR already has worldwide rights to resulting products, excluding the EU and certain other countries. AltaRex...
BioCentury | Jun 9, 2003
Clinical News

OvaRex MAb: Phase II data; Phase III

...and chemotherapy. Data were presented at the American Society of Clinical Oncology meeting in Chicago. AltaRex...
BioCentury | Jun 2, 2003
Finance

Restructuring watch

...reduce its quarterly cash burn to $6-$7 million. $49.1 3/31 $7.5 1Q ended 3/31 5/15/03 AltaRex...
BioCentury | May 19, 2003
Company News

AltaRex Corp. board of directors update

AltaRex Corp. (TSE:AXO; ALXFF), Waltham, Mass. Business: Cancer Appointed: Antoine Noujaim, AXO founder Resigned: Richard Bagley WIR Staff...
BioCentury | May 19, 2003
Company News

AltaRex Corp. management update

AltaRex Corp. (TSE:AXO; ALXFF), Waltham, Mass. Business: Cancer Resigned: Richard Bagley as president and CEO; he will be replaced by AXO founder Antoine Noujam WIR Staff cancer...
BioCentury | May 12, 2003
Clinical News

OvaRex MAb: Phase II comparability data; Phase III

...I and II studies as well as other ongoing Phase II trials in the U.S. AltaRex...
Items per page:
1 - 10 of 111